What the Commission Recommended
A special commission appointed by the Israeli Health Ministry, led by Dr. Gilad Bodenheimer, head of the mental health division, presented its report on May 3, 2026. Core recommendation: the prescription and dispensing of smokable cannabis flower should be terminated within three years. Patients should transition from flower to extracts and precision inhalers instead.
📑 Inhaltsverzeichnis
The commission justified its position by citing risks associated with inhalant smoke products and what it viewed as inconsistent cannabinoid uptake. It also provided market data showing the scope of the issue: the number of cannabis patients in Israel rose from 33,000 in 2019 to approximately 140,000 in 2025. Sixty-two percent of patients consume more than 30 grams monthly, and 88 percent use high-potency THC preparations. Ninety-eight percent of licensed purchases are smokable flower, often mixed with tobacco.
The Health Minister’s Rapid Reversal
Days after the recommendation’s publication, Health Minister Haim Katz applied the brakes. He cited technical commentary from within his own ministry and instructed the director general to suspend all implementation steps. His position: even if stronger oversight is necessary, a functioning supply pathway should not be dismantled. The commission’s recommendation remains politically suspended, though not formally withdrawn.
The underlying concern is that an abrupt switch to extracts would leave thousands of patients without adequate supply. The Israeli Medical Association had already advocated for oil-based administration as the primary delivery method in 2023, though that recommendation never translated into clinical practice.
Why the Parallel to German Policy Matters
Germany’s Federal Health Ministry has spent months debating reform of its Medical Cannabis Act. The most prominent point of contention is a proposed mail-order ban on cannabis flower, affecting telemedicine platforms and pharmacies in particular. Behind the procedural question lies a substantive debate about the role of flower: should it remain the standard form of delivery, or should regulatory pressure gradually shift patients toward extracts and oils?
The Israeli case demonstrates how polarized this debate has become internationally. Medical associations and ministerial commissions argue from addiction prevention and pharmacokinetics perspectives, while patient organizations and market participants emphasize supply reality and individual therapeutic choice. The reflection in German policy discourse is evident. More context on the German debate is available in our analysis of Medical Cannabis Act disputes and threats to patient access and planned reforms and their supply consequences.
Market Consequences and Potential Supply Chain Shifts
Israel operates one of the world’s most significant cannabis industries. Companies like Tikun Olam, Panaxia, and IMC primarily serve the domestic market but increasingly export to Europe. A flower ban would impact strain development, genetic research, and export strategies. The halt to the recommendation at least gives the industry time to prepare for a potential transition pathway.
For German importers, the question is relevant because if Israel completed a transition to extracts, it could reshape the European market. If Israeli manufacturers concentrate production on extracts and inhalers, the supply available to German pharmacies—currently heavily flower-focused—would shift accordingly.
What Comes Next
A final decision on the recommendation remains pending. Observers expect the Health Ministry to develop a tiered model that maintains flower preparations for select indications while simultaneously promoting standardized extracts. A decision by fall 2026 is possible, and a timely resubmission to the ministerial plenum cannot be ruled out.
For German patients and providers, the Israeli case should inform the current Medical Cannabis Act discussion. A ban on smokable flower is not currently under discussion at the European level, but regulatory pressure on telemedicine-based flower distribution is very much alive.
Frequently Asked Questions
Who recommended the flower ban in Israel?
A special commission appointed by the Health Ministry and led by Dr. Gilad Bodenheimer published the report on May 3, 2026. It recommends ending medical cannabis smoking within three years and transitioning to extracts and inhalers.
Why was the recommendation halted?
Health Minister Haim Katz argued that restrictive policy reversal was the wrong approach. Based on technical commentary from his own ministry, he instructed the director general to freeze all implementation steps. The recommendation remains politically suspended but is not formally withdrawn.
How many patients does Israel have?
The number of cannabis patients rose from 33,000 in 2019 to approximately 140,000 in 2025. Ninety-eight percent of licensed purchases are smokable flower, often combined with tobacco.
Does this affect Germany?
Not directly. The German market is primarily supplied by Canada, Portugal, and Denmark. Indirectly, however, an Israeli ban could influence the product mix of European suppliers and further intensify the German debate about flower’s regulatory role.
What happens next?
Further ministerial review is likely. A tiered model permitting flower for select indications while promoting extracts through regulation is currently discussed as a compromise position. A decision is not expected before fall 2026.
Sollten Cannabisblüten im medizinischen Bereich weiter erlaubt bleiben?
Sources: Business of Cannabis International Round-Up (May 13, 2026); Times of Israel and Ynetnews coverage of the May 3, 2026 report; International CBC on Health Minister Haim Katz’s halt decision; Stratcann.
Branchen-Update
News, Analysen und Reportagen — mehrmals im Monat direkt in dein Postfach.
Folge uns
